Trautmann B, Wittekind C, Strobel D, Meixner H, Keymling J, Gossner L, Ell C, Hahn E G
Department of Medicine I, University of Erlangen-Nuremberg, Germany.
Eur J Gastroenterol Hepatol. 1996 Aug;8(8):799-804.
In Barrett's adenocarcinomas, in contrast to squamous oesophageal carcinomas, K-ras point mutations are thought to be a frequent event. The frequency of K-ras point mutations in premalignant forms of Barrett's oesophagus (metaplasia, dysplasia) leading to adenocarcinoma with increased risk is currently not known. To establish the frequency of K-ras mutations in premalignant forms of Barrett's oesophagus, we investigated oesophageal biopsy specimens with Barrett's metaplastic and dysplastic epithelium for point mutations in the K-ras gene/codons 12, 13.
A total of 412 biopsies from patients with Barrett's oesophagus were histologically classified into biopsies with metaplasia (n = 252), dysplasia (n = 105) and adenocarcinoma (n = 11), as well as biopsies distant from disease (normal, n = 37 and hyperplastic squamous epithelium, n = 7).
DNA from biopsy specimens was amplified by polymerase chain reaction (PCR) with a modified primer for generating a restriction site in the case of wild type in codon 12. Wild-type or point mutations in the K-ras gene/codons 12, 13 were detected by restriction fragment length analysis of the PCR products.
Point mutations in K-ras/codon 12 were found in 9 biopsies (n = 1 in metaplasia, n = 4 in dysplasias, n = 4 in adenocarcinomas). All the other biopsies showed the wild type of K-ras/codon 12. No K-ras/codon 13 mutation (GGCgly-->GACasp) was observed.
Mutations in K-ras/codon 12 were rarely found in premalignant forms of Barrett's oesophagus. Whereas the screening for K-ras point mutations in metaplastic sites of Barrett's epithelium seems not to be of practical value, the screening for mutations in dysplastic lesions might be helpful to estimate the individual risk for progression of Barrett's epithelium to adenocarcinoma. A further evaluation in larger numbers of patients is needed.
与鳞状食管癌不同,K-ras点突变在巴雷特腺癌中被认为是常见事件。导致腺癌风险增加的巴雷特食管癌前病变(化生、发育异常)中K-ras点突变的频率目前尚不清楚。为确定巴雷特食管癌前病变中K-ras突变的频率,我们研究了具有巴雷特化生和发育异常上皮的食管活检标本中K-ras基因/密码子12、13的点突变情况。
对412例巴雷特食管患者的活检标本进行组织学分类,分为化生活检(n = 252)、发育异常活检(n = 105)、腺癌活检(n = 11),以及远离病变的活检(正常,n = 37;增生性鳞状上皮,n = 7)。
活检标本的DNA通过聚合酶链反应(PCR)扩增,使用一种改良引物,在密码子12为野生型时产生一个限制性位点。通过对PCR产物进行限制性片段长度分析来检测K-ras基因/密码子12、13中的野生型或点突变。
在9例活检标本中发现了K-ras/密码子12的点突变(化生中1例,发育异常中4例,腺癌中4例)。所有其他活检标本均显示K-ras/密码子12为野生型。未观察到K-ras/密码子13突变(GGC甘氨酸→GAC天冬氨酸)。
在巴雷特食管的癌前病变中很少发现K-ras/密码子12的突变。虽然在巴雷特上皮化生部位筛查K-ras点突变似乎没有实际价值,但筛查发育异常病变中的突变可能有助于评估巴雷特上皮进展为腺癌的个体风险。需要对更多患者进行进一步评估。